Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2002 Mar;86(3):190–193. doi: 10.1136/adc.86.3.190

Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease

H Wyatt 1, A Dhawan 1, P Cheeseman 1, G Mieli-Vergani 1, J Price 1
PMCID: PMC1719124  PMID: 11861239

Abstract

Aim: To determine whether serum hyaluronic acid (HA) concentrations are abnormal in patients with cystic fibrosis (CF) liver disease, and if so, whether the abnormality is associated with disease severity.

Methods: A total of 74 patients with CF were assessed for evidence of liver involvement as indicated by clinical, ultrasound, and biochemical findings. Serum hyaluronic acid concentrations were measured and compared with concentrations in 293 normal controls. Lung function in the CF patients was also recorded.

Results: Thirty four CF patients had no evidence of liver disease; in these, serum HA concentrations were similar to those in healthy controls (median (range): 16.1 (9.4–75.1) v 15 (1–77) µg/l). Nineteen CF patients had established liver disease detected by clinical and ultrasound examination, with significantly increased HA concentrations (56.1 (26–355) µg/l). Serum HA concentrations were also significantly increased, although to a lesser extent, in 21 CF patients with an abnormal liver ultrasound scan alone (22.4 (9.5–43.4) µg/l). There was no correlation between serum HA concentration and lung function.

Conclusion: Serum HA concentrations were significantly increased in children with clinical or ultrasound evidence of liver disease, being higher in those with more advanced hepatic damage. Despite the inflammation and fibrosis present in CF lungs there was no correlation between HA concentration and lung function, suggesting that high concentrations were a failure of hepatic clearance rather than overproduction in the lung. Longitudinal measurement of HA concentrations may prove a useful marker for the development of significant liver damage in CF patients.

Full Text

The Full Text of this article is available as a PDF (126.8 KB).

Figure 1 .

Figure 1

Open in a new tab

Serum HA concentrations in normal controls and CF patients according to degree of liver involvement. Median values are indicated by a horizontal bar.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bjermer L., Lundgren R., Hällgren R. Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Thorax. 1989 Feb;44(2):126–131. doi: 10.1136/thx.44.2.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Colombo C., Battezzati P. M. Hepatobiliary manifestations of cystic fibrosis. Eur J Gastroenterol Hepatol. 1996 Aug;8(8):748–754. [PubMed] [Google Scholar]
  3. Colombo C., Battezzati P. M., Strazzabosco M., Podda M. Liver and biliary problems in cystic fibrosis. Semin Liver Dis. 1998;18(3):227–235. doi: 10.1055/s-2007-1007159. [DOI] [PubMed] [Google Scholar]
  4. Colombo C., Crosignani A., Assaisso M., Battezzati P. M., Podda M., Giunta A., Zimmer-Nechemias L., Setchell K. D. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology. 1992 Oct;16(4):924–930. doi: 10.1002/hep.1840160412. [DOI] [PubMed] [Google Scholar]
  5. Dean T. P., Dai Y., Shute J. K., Church M. K., Warner J. O. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res. 1993 Aug;34(2):159–161. doi: 10.1203/00006450-199308000-00010. [DOI] [PubMed] [Google Scholar]
  6. Dhawan A., Trivedi P., Cheeseman P., Baker A. J., Howard E. R., Mieli-Vergani G. Serum hyaluronic acid as an early prognostic marker in biliary atresia. J Pediatr Surg. 2001 Mar;36(3):443–446. doi: 10.1053/jpsu.2001.21622. [DOI] [PubMed] [Google Scholar]
  7. Floreani A., Zappalà F., Mazzetto M., Naccarato R., Plebani M., Chiaramonte M. Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease. Dig Dis Sci. 1994 Jan;39(1):9–14. doi: 10.1007/BF02090053. [DOI] [PubMed] [Google Scholar]
  8. Fraser J. R., Laurent T. C. Turnover and metabolism of hyaluronan. Ciba Found Symp. 1989;143:41-53; discussion 53-9, 281-5. [PubMed] [Google Scholar]
  9. Gressner A. M. Liver fibrosis: perspectives in pathobiochemical research and clinical outlook. Eur J Clin Chem Clin Biochem. 1991 May;29(5):293–311. [PubMed] [Google Scholar]
  10. Hällgren R., Eklund A., Engström-Laurent A., Schmekel B. Hyaluronate in bronchoalveolar lavage fluid: a new marker in sarcoidosis reflecting pulmonary disease. Br Med J (Clin Res Ed) 1985 Jun 15;290(6484):1778–1781. doi: 10.1136/bmj.290.6484.1778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Laurent T. C., Fraser J. R. Hyaluronan. FASEB J. 1992 Apr;6(7):2397–2404. [PubMed] [Google Scholar]
  12. Lindblad A., Glaumann H., Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology. 1998 Jan;27(1):166–174. doi: 10.1002/hep.510270126. [DOI] [PubMed] [Google Scholar]
  13. Lindqvist U. Is serum hyaluronan a helpful tool in the management of patients with liver diseases? J Intern Med. 1997 Jul;242(1):67–71. doi: 10.1046/j.1365-2796.1997.00176.x. [DOI] [PubMed] [Google Scholar]
  14. Lindqvist U., Laurent T. C. Serum hyaluronan and aminoterminal propeptide of type III procollagen: variation with age. Scand J Clin Lab Invest. 1992 Nov;52(7):613–621. doi: 10.3109/00365519209115504. [DOI] [PubMed] [Google Scholar]
  15. Nyberg A., Engström-Laurent A., Löf L. Serum hyaluronate in primary biliary cirrhosis--a biochemical marker for progressive liver damage. Hepatology. 1988 Jan-Feb;8(1):142–146. doi: 10.1002/hep.1840080127. [DOI] [PubMed] [Google Scholar]
  16. O'Connor P. J., Southern K. W., Bowler I. M., Irving H. C., Robinson P. J., Littlewood J. M. The role of hepatobiliary scintigraphy in cystic fibrosis. Hepatology. 1996 Feb;23(2):281–287. doi: 10.1002/hep.510230213. [DOI] [PubMed] [Google Scholar]
  17. Sahu S. C. Hyaluronic acid. An indicator of pathological conditions of human lungs? Inflammation. 1980 Mar;4(1):107–112. doi: 10.1007/BF00914107. [DOI] [PubMed] [Google Scholar]
  18. Scott-Jupp R., Lama M., Tanner M. S. Prevalence of liver disease in cystic fibrosis. Arch Dis Child. 1991 Jun;66(6):698–701. doi: 10.1136/adc.66.6.698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Shapiro J. M., Smith H., Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut. 1979 Feb;20(2):137–140. doi: 10.1136/gut.20.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sinaasappel M. Hepatobiliary pathology in patients with cystic fibrosis. Acta Paediatr Scand Suppl. 1989;363:45–51. doi: 10.1111/apa.1989.78.s363.45. [DOI] [PubMed] [Google Scholar]
  21. Stern R. C., Stevens D. P., Boat T. F., Doershuk C. F., Izant R. J., Jr, Matthews L. W. Symptomatic hepatic disease in cystic fibrosis: incidence, course, and outcome of portal systemic hunting. Gastroenterology. 1976 May;70(5 PT1):645–649. [PubMed] [Google Scholar]
  22. Trivedi P., Cheeseman P., Mowat A. P. Serum hyaluronic acid in healthy infants and children and its value as a marker of progressive hepatobiliary disease starting in infancy. Clin Chim Acta. 1993 Apr 16;215(1):29–39. doi: 10.1016/0009-8981(93)90246-z. [DOI] [PubMed] [Google Scholar]
  23. Trivedi P., Dhawan A., Risteli J., Risteli L., Mirza M., Cheeseman P., Mowat A. P. Prognostic value of serum hyaluronic acid and type I and III procollagen propeptides in extrahepatic biliary atresia. Pediatr Res. 1995 Oct;38(4):568–573. doi: 10.1203/00006450-199510000-00016. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES